Regulatory consultant EAS Strategic Advice (Brussels) said it expects other member states to follow suit with their own guidelines in 2013.
Belgium has become the first EU member state to publish guidelines on the flexibility of health claims wording under the EU’s Nutrition and Health Claims Regulation. By December 14, 2012, companies selling product in the EU must ensure their health claims wording adheres to the EU regulation’s permitted claims list.
Belgium published its guidelines on October 31. Regulatory consultant EAS Strategic Advice (Brussels) said it expects other member states to follow suit with their own guidelines in 2013.
Among the topics covered in the Belgian guidelines is use of the wording contributes to and normal. “They also cover how the claims wording related to a health function may be reformulated and/or enriched with certain additional information (mainly from European Food Safety Authority opinions),” EAS stated in a press release. The guidelines refer to both Article 13.1 health claims and Article 14 disease risk claims.
“The guidelines issued by Belgium provide an idea of the expected variations of permitted claims wording practices in national markets,” said EAS regulatory affairs manager Stefanie Geiser. “They also illustrate that there may be space for negotiations with national authorities on specific product cases based on acceptable market practice in other EU countries. An overall positive trend is that the Belgian authorities show some flexibility on the permission to enrich/amend authorized Article 13.1 claims wordings in line with related functions expressed by EFSA in its opinions.”
EAS is holding a workshop in Brussels on December 11 on the Nutrition and Health Claims Regulation.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.